approvalsWatch: Neurology 130217
US FDA Approvals
The FDA has approved deflazacort as a tablet and oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 5 years and older. The first corticosteroid to be approved for this condition, deflazacort has been shown to be effective in improving muscle strength during 12 weeks of treatment versus placebo, and maintaining stable overall muscle strength for up to 52 weeks. Some of the most common side effects associated with the drug are facial puffiness, weight gain, increased appetite, and upper respiratory tract infection.